Cancer Molecular Imaging, Nanotechnology and Theranostics

癌症分子成像、纳米技术和治疗学研究中心（CMINT） 摘要 癌症分子成像，纳米技术和治疗诊断学研究计划（CMINT）拥有 具有互补专业知识的成功领导者，Johannes Czernin，MD（总监），Caius Radu，MD（合作伙伴）， 导演）和杰弗里·津克博士（联合导演）。该计划的主要目标是促进翻译 成像、纳米颗粒设计和递送以及治疗诊断学，旨在改善癌症患者的预后 通过将发现转移到临床前和临床应用。CMINT计划科学是高度互动的， 跨学科，其45名教师来自四个加州大学洛杉矶分校的学校和合作机构，加州理工学院， 代表16个基础和临床部门。成员在生物学方面具有多样和互补的专业知识， 核医学，物理学，纳米技术，泌尿学，放射学，放射肿瘤学，药物开发， 工程、图像重建、化学、放射化学和疾病的动物模型。CMINT 计划合并前癌症分子成像（CMI）研究计划与进化和有机 发展先前的癌症纳米技术（CN）研究计划，结合新的重点， 重粒子治疗和成像截至2019年3月1日，该计划的直接成本资金为10，033，965美元， 其中包括来自NCI的590万美元（59%）和895万美元（89%）的直接成本同行评审资金。程序 在上一个项目期间，发现了1，109篇出版物，其中23%是计划内的 29%是跨项目合作。此外，49%的出版物 与外部机构的合作，35%是在高影响力（IF ≥10，或领域领先）期刊。的 该计划贡献了14项专利，5项已批准的IND和9家初创公司。在上一个项目期间， 有93项临床试验由计划成员发起，累计11，807人。CMINT有四个 具体目标是推进主要计划目标和目的，包括：（1）开发仪器， 分析工具和新的分子成像方法;（2）成像免疫反应和对 免疫疗法;（3）工程纳米技术为基础的成像和治疗输送系统;和（4） 将诊断和治疗诊断方法转化为临床。在这些目标中， 揭示并靶向肽受体放射性核素（PRRT）和放射性配体（RLT）的耐药机制 治疗，并评估具有高翻译潜力的新型治疗诊断对。其他研究包括 开发和翻译新的分子成像技术和方法，以改善诊断 和治疗癌症，并使用光谱的光学，放射性[PET/SPECT]，和MRI成像和非- 成像方法，如质谱，以扩大分子成像和治疗的范围。CMINT 计划成员继续强调机会，并在PET成像方面处于领先地位，同时在以下方面建立实力： 包括mpMRI在内的其他成像方式，沿着在纳米颗粒剂中添加强大的概念 交付和治疗诊断学的核心工作。

CANCER MOLECULAR IMAGING, NANOTECHNOLOGY, AND THERANOSTICS RESEARCH PROGRAM (CMINT) ABSTRACT The Cancer Molecular Imaging, Nanotechnology, and Theranostics Research Program (CMINT) boasts accomplished leaders with complementary expertise, Johannes Czernin, MD (Director), Caius Radu, MD (Co- Director), and Jeffrey Zink, PhD (Co-Director). The primary Program objective is to advance translational imaging, nanoparticle design and delivery, and theranostics with the goal of improving cancer patient outcomes by moving discoveries to preclinical and clinical applications. CMINT Program science is highly interactive and transdisciplinary, with its 45 faculty members drawn from four UCLA schools and partner institution, Caltech, representing 16 basic and clinical departments. Members have diverse and complementary expertise in biology, nuclear medicine, physics, nanotechnology, urology, radiology, radiation oncology, drug development, engineering, image reconstruction, chemistry, radiochemistry, and animal models of disease. The CMINT Program merges the former Cancer Molecular Imaging (CMI) Research Program with the evolution and organic development of the prior Cancer Nanotechnology (CN) Research Program, combined with a new emphasis on heavy particle therapy and imaging. As of March 1, 2019, the Program has $10,033,965 in direct cost funding, including $5.9M (59%) from the NCI, and $8.95M (89%) in total direct cost peer-reviewed funding. Program discoveries resulted in 1,109 publications over the prior project period, of which 23% are intra-programmatic collaborations and 29% are inter-programmatic collaborations. In addition, 49% of publications represent collaborations with external institutions and 35% are in high-impact (IF ≥10, or field leading) journals. The Program contributed 14 patents, five approved INDs, and nine start-up companies. In the prior project period, there were 93 clinical trials initiated by Program members with 11,807 individuals accrued. CMINT has four specific aims to advance the primary Program objective and goal, including: (1) Developing instrumentation, analytical tools, and novel molecular imaging approaches; (2) Imaging immune responses and responses to immunotherapy; (3) Engineering nanotechnology-based imaging and therapeutic delivery systems; and (4) Translating diagnostic and theranostic approaches into the clinic. Embedded within these aims are studies to uncover and then target resistance mechanisms in peptide receptor radionuclide (PRRT) and radioligand (RLT) therapies, and to evaluate novel theranostic pairs with high translational potential. Additional studies include developing and translating new molecular imaging technologies and methodologies to improve the diagnosis and treatment of cancer, and using a spectrum of optical, radioactive [PET/SPECT], and MRI imaging and non- imaging approaches, such as mass-spectrometry, to extend the reach of molecular imaging and therapy. CMINT Program members continue to emphasize opportunities and lead in PET imaging while building strength in additional imaging modalities that include mpMRI, along with adding powerful concepts in nanoparticle agent delivery and theranostics to its core efforts.